ANI Pharmaceuticals Inc
NASDAQ:ANIP
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Price:
62.39 USD
-2.16%
Market Closed
Updated:
May 18, 2024
ANI Pharmaceuticals Inc
Cost of Revenue
|
ANI Pharmaceuticals Inc
Cost of Revenue Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
Cost of Revenue
-$181.5m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-33%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cost of Revenue
-$26.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cost of Revenue
-$11B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cost of Revenue
-$16.3B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cost of Revenue
-$15.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cost of Revenue
-$7.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-4%
|
See Also
What is ANI Pharmaceuticals Inc's Cost of Revenue?
Cost of Revenue
-181.5m
USD
-181.5m
USD
Based on the financial report for Dec 31, 2023, ANI Pharmaceuticals Inc's Cost of Revenue amounts to -181.5m USD.
What is ANI Pharmaceuticals Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-33%
-33%
Over the last year, the Cost of Revenue growth was -31%. The average annual Cost of Revenue growth rates for ANI Pharmaceuticals Inc have been -28% over the past three years , -20% over the past five years , and -33% over the past ten years .
You don't have any saved screeners yet
